MAPT and Alzheimer disease: Pioglitazone acts similarly as Rosiglitazone by reducing tau and Aβ deposits in the hippocampus, and improving neuronal plasticity and learning in AD.393–395 These studies collectively suggest that IR contributes to AD pathogenesis through multiple pathways.